All-In Interview Show Host

1. Key Themes

The Spotify Playbook, Re-Run in Healthcare

Ek is deliberately repeating the Spotify go-to-market sequence: spend years perfecting the product in a small, hard-but-favorable home market, prove it, then expand to larger markets. The parallel is explicit, and the timing is nearly identical (roughly five years of development before the US).

Ek on Spotify: "I started Spotify in 2006. I was 23 at the time... We launched in late 2008... And then in 2011, 15 years ago now, we launched in the US." 00:02:15

On Neko: "we started the company eight years ago in 2018. And we started it in Sweden in 2023. So it took us five years to develop the product, try it out in Sweden. And then once we've proven it in Sweden, we took it to the UK and did it there. And then from there on, now we're launching in the US. So it's an exact Spotify playbook again, but this time in healthcare." 00:06:10

The Thesis: Chronic Disease Is a Data Problem

Neko's core belief is that healthcare's inability to shift from reactive to preventative care comes down to a lack of longitudinal, multimodal data. Everyone agrees on the destination; the disagreement is about how to get there.

Ek: "everyone in the entire healthcare industry is in agreement that we have to take healthcare from reactive to preventative health. But then now all the disagreement starts, which is how do you do that? And our view... is really that it all starts with having better data." 00:11:52

On what kind of data: "you need a lot more data than you have today, both from each modality that you gather data, but also across multiple modalities. And you need it longitudinally. So you need it over time." 00:13:03

Why Now: Sensors, Cheap Electronics, and AI

Ek ties Neko's timing to two converging curves: smartphone-driven sensor and electronics commoditization, and machine learning maturing into modern AI.

Ek: "one of the biggest innovations, of course, is the smartphones. And we've had more and more sensors packed into those smartphones. So there's more and more... cheap electronics that's available to us." 00:13:23 He adds the Spotify analogy: "The more data we're able to gather, the better predictions we're able to give you about what song to play next. And so this is exactly the same thing that you now need to do in healthcare." 00:14:19

Vertical Integration as the Cost Weapon

Neko builds facilities, staffs its own clinicians, designs its own diagnostic equipment, and writes its own software. This lets it price a full-body diagnostic experience at $499 with positive unit economics.

Ek: "It is a reinvented healthcare experience from the ground up, vertically integrated. We do everything from building our own facilities to having our own nurses and doctors on staff to building our own diagnostic equipment and doing everything on our own on the software side." 00:15:13

On economics: "the benefit of being vertically integrated is that we've been able to build everything ourselves, which means we can also cut costs in a pretty dramatic way. So within that $500 a year, the unit economics are positive. And we have clinics today that are profitable." 00:25:46

AI + Clinicians as the Correct Healthcare Architecture

The dermatology workflow is a template for how Ek sees healthcare: AI does exhaustive, memory-perfect pattern detection, and humans handle judgment and communication, with specialists as the final tier.

Ek: "We first have an AI system that flag possible risk factors. And then we have a human clinician that then goes through and reviews those as well. And should we even at that point find something, we then have expert dermatologists on staff, multiple of them that then also reviews that result." 00:20:45 And: "It should seamlessly be both AI and amazing clinicians in a great package experience." 00:21:42

Misaligned Incentives Are the Root Cause of Healthcare's Dysfunction

Ek's diagnosis is structural: the system was designed for acute infectious disease, and employer-tied insurance with short job tenures kills the appetite for long-payback preventative investment. His workaround is to shrink the required investment so the ROI hurdle falls.

Ek: "the entire system is predicated on and the healthcare system was built around a time when we were dealing with infectious disease... So all the incentives are really around that, which means we're fixing you acutely when there's massive amounts of symptoms." 00:28:42 On employment tenure: "the average tenure of your employment is not that very long. It means that you may have only two, three years at one employer and then you switch. And when you switch, you switch insurers too." 00:29:10

Publish Data to Build the Longitudinal Evidence Base

Neko releases annual outcome data and runs clinical trials, treating data generation as a strategic asset for the whole field, not just for the company.

Ek: "We've done more than 100,000 scans already. So we actually publish data every year... around 1% of our members have a serious underlying medical situation that is undiagnosed that we discover." 00:17:54 On trials: "We've done four already. We have two underway. We have another four we're going." 00:32:12

The Behavioral Effect: Visibility Drives Change

A less obvious finding is that the sickest members improve the most, suggesting the product functions as a behavior-change engine as well as a diagnostic.

Ek: "the most encouraging thing we're finding now, as we've done these studies for three years in a row, is that the people with the worst health status are the ones that are improving the most." 00:18:42

Open vs. Closed AI Will Coexist, and Spotify Uses Both

Ek's practical stance is hybrid: use frontier models where they win, use fine-tuned models where cost, efficiency, or tunability matter.

Ek: "we're obviously using a lot of the frontier models, but we have a bunch of fine-tuned models ourselves too. And we tend to do both. And that is actually making us more innovative." 00:40:40

The Industry's AI Narrative Is Too Negative

Ek argues the tech industry has failed to publicize concrete, positive AI use cases, and lists his own.

Ek: "I think we as an industry have done a terrible disservice of not talking about all the really, really crazy positive stuff that we can use AI for that actually greatly benefits everyone." 00:38:52

2. Contrarian Perspectives

Compute, Not Model Capability, Is the Better Regulatory Lever

Ek says he is surprised the AI safety debate hasn't focused on the amount of compute used, as opposed to the model's intelligence. His logic is that dangerous, large-scale misuse requires large-scale compute; a home PC running an open-source model is unlikely to cause "an enormous cyber thing." Friedberg extends it into a certification-for-compute regime.

Ek: "I'm surprised that people haven't talked about sort of the amount of computes. So if you think about it, for me, this isn't about just the intelligence itself of a single model... if I'm using a hundred thousand GPUs for something, that's probably going to be a lot more powerful than if I'm running an open source model on my home PC." 00:41:35 Friedberg: "compute as a key metric of defensibility, and that's really where we can start to build guardrails around who can have access to the most compute and how do you get certified for compute as opposed to certified for software." 00:42:42

Most Things Are Going Well; Founders Should Attack the Ones That Aren't

Against the doom-oriented mood, Ek says the up-and-to-the-right technology curve means the highest-leverage work is on the domains that are deteriorating despite rising spend.

Ek: "a lot of people just talk about sort of all the stuff that's going bad in the world. But my view is that actually most things are going pretty well. And it's kind of up and to the right on the technology curve... But I try to focus on the problems that aren't going that well." 00:07:50

"Founders Should Build, Not Invest"

Ek discovered he loved building more than investing, and Friedberg goes further, saying advising and board seats are unproductive. The contrarian implication is that the highest-return move for a capable operator is often to stop allocating and go operate.

Ek: "I kind of just realized that I loved building way more than I loved investing." 00:09:06 Friedberg: "you find amazing entrepreneur, founder, CEOs. Give them money and never look at it again and you'll be fine... if that's really what you're passionate about and you have the activity or the agency, it's to step in and do it yourself." 00:09:26

Confident Expert Consensus Is Usually Wrong

Ek argues that the instant-expert phenomenon (virology, supply chains, military strategy) shows why strong opinions on how to pace AI should be held loosely, and declines to take a strong side on pausing.

Ek: "everyone expresses these things with such extreme confidence. And it turns out most of the time we ended up being completely wrong, even the biggest experts." 00:37:12

Cost Barriers, Not Capability Barriers, Are the Real Blocker in Preventative Care

Rather than arguing insurers are irrational, Ek argues the payback horizon is too long relative to the size of the bet, so the fix is making the bet small.

Ek: "if we lower it, so it may not be a million dollars. It may be, you know, I make it up tens of thousands of dollars. Even if that payback time was 10 or 20 years, I think that there will be a higher propensity and likelihood for a pickup on that." 00:30:32

3. Companies Identified

Neko Health

Preventative health startup co-founded by Daniel Ek and Hjalmar Nilsonne (referred to in the transcript as "Yelmer"/"Yalmer"). Founded 2018, launched in Sweden in 2023, then the UK, and now New York (300 Lafayette Street), with Miami and DC planned. Why mentioned: The centerpiece of the episode. A vertically integrated, AI-plus-clinician full-body scan at $499 with positive unit economics and profitable clinics. Quote: "the average person at NECO today has 950 moles." 00:19:39 And: "We're launching in Florida as well, in Miami, and we're launching in DC. And we're going to try to launch all over the US in the coming 12 to 24 months." 00:50:06

Spotify

Audio streaming platform Ek co-founded in 2006; 700M+ active users and 300M+ premium subscribers. Why mentioned: The original proof of Ek's playbook, and now a heavy user of both frontier and fine-tuned models. Also a growing podcast destination that syndicates to other platforms through open standards. Quote: "we also through our platform, aggregate and distribute podcast onto a lot of the other podcasting platforms... And we're obviously doing that through open standards." 00:45:48

Prima Materia

Investment/company-building vehicle Ek created with Shak Hoghouse (referred to as "Shaq" in the transcript). Why mentioned: Ek's "pay it forward" effort to be "the greatest co-founder you could possibly find." Quote: "how do we pay it forward and kind of almost be like the greatest co-founder you could possibly find? That's the ambition of Prima Materia." 00:27:05

Stardoll

Swedish digital-goods and subscription platform (originally "Paper Doll Heaven" from Turku, Finland) where Ek served as technical lead before Spotify. Backed by Index Ventures and Sequoia. Why mentioned: Origin story showing Ek's early technical turnaround skill and an early example of digital goods and subscriptions in Sweden. Quote: "I think the average page load time at that time was like four minutes... So we basically re-architected the website. I hired an entirely new technical team and brought it down to under a second of load time. And obviously the traffic exploded, Sequoia invested." 00:48:58

Function Health

Blood-work-focused preventative health service. Why mentioned: A peer offering in the same broad category, priced around $350-$400 with blood work only, compared against Neko's multimodal scope. Quote: "You also have Function Health and Superpower, two other great services, about $350, $400. They just do blood work." 00:22:38

Superpower

Preventative health/lab-testing service. Why mentioned: Named alongside Function Health as a blood-work-only comparable. Quote: "You also have Function Health and Superpower, two other great services, about $350, $400. They just do blood work." 00:22:38

Whoop

Wearable health-tracking company that now offers lab testing through Quest. Why mentioned: Host flagged it as an example of wearables moving toward blood-work integration, which could be correlated with Neko's data. Quote: "I noticed Whoop offering labs now through Quest." 00:33:24

Oura

Wearable health-tracking ring (transcribed as "Aura"). Why mentioned: One of the wearables whose sleep/recovery data could be correlated with clinical data; it can write to Apple Health, which Neko imports. Quote: "already today, we do allow you to import your Apple Health data. So if you do have wearable data, we will take that." 00:34:18

Quest Diagnostics

Clinical laboratory network. Why mentioned: Partner through which Whoop now offers lab testing. Quote: "I noticed Whoop offering labs now through Quest." 00:33:24

Apple (Apple Health / Apple Watch)

Consumer hardware and health data platform. Why mentioned: Neko lets members import Apple Health data; the host cited Apple Watch data correlated with blood work as a key future opportunity. Quote: "You start with Apple Watches, you start correlating that data with the blood work." 00:33:24

Fitbit

Wearable fitness tracker. Why mentioned: Named in passing among wearables that produce data that could be linked to clinical data. Quote: "the Auras, the Whoops, the Fitbits." 00:33:24

Forward

Preventive-care clinic startup with its own instrumentation. Why mentioned: Friedberg cited it as a prior attempt at integrated preventative checkup centers, asking what makes Neko novel. Quote: "there was one medical there was forward. I mean, there were a few other kind of attempts at making these integrated centers where you go in and get preventative checkups with their own instrumentation." 00:17:32

One Medical

Membership-based primary care provider. Why mentioned: Named by Friedberg as an earlier attempt at the integrated preventative model. Quote: "there was one medical there was forward." 00:17:32

Index Ventures

Venture capital firm. Why mentioned: Took a majority stake in Paper Doll Heaven and helped rebrand it into Stardoll. Quote: "Index Ventures had invested in it and taking kind of a majority stake to help doing this because they had no idea of scaling this site." 00:48:00

Sequoia Capital

Venture capital firm. Why mentioned: Invested in Stardoll after Ek's technical turnaround. Quote: "And obviously the traffic exploded, Sequoia invested." 00:49:25

RIAA

Recording Industry Association of America. Why mentioned: Context for the pre-Spotify era: it sued individual consumers over piracy. Quote: "there was an organization called the RIAA that went around and actually sued individual consumers in the US for illegally downloading music." 00:02:33

Napster / Kazaa

Peer-to-peer music piracy services. Why mentioned: Illustrate the piracy environment Spotify emerged into. Quote: "we had Napster, we had Kazaa, we had all these things." 00:02:33

iTunes

Apple's digital music store. Why mentioned: Its absence in Sweden meant "there was literally no legal options" for consumers. Quote: "iTunes actually wasn't even available in the marketplace. There was literally no legal options." 00:04:23

Cray

Supercomputer maker. Why mentioned: Friedberg's historical analog for compute-based access controls that later became obsolete as hardware commoditized. Quote: "Today, a Cray supercomputer, I think, is less power than a washing machine or something." 00:43:37

Northwest Registered Agent and Creative Planning

Sponsors read in the episode. Why mentioned: Sponsor reads; not endorsed by the guest. Quote: "Creative planning, where wealth works together." 00:01:45

4. People Identified

Daniel Ek

Co-founder and Executive Chairman of Spotify (since January 1), co-founder of Neko Health, co-creator of Prima Materia. Why mentioned: Guest. Twenty-year operator who negotiated with the notoriously difficult music industry and is now repeating the arc in healthcare. Quote: "if this really is as bad as you think it is, then you just shut it down after a year, but you still made the bonus. And if this actually works, you win as well. So you win no matter what." 00:05:19

Martin Lorentzon

Ek's Spotify co-founder (called "Martin" in the transcript). Why mentioned: His persistent "what if" questioning is what pushed Ek from calling music "a really stupid idea" to launching Spotify. Quote: "Martin asked me like, well, you know, if you could do anything you'd like to do, what would you do?... And then he kept asking these, what if questions. And eventually I ran out of reasons to say it." 00:03:01

Hjalmar Nilsonne

Co-founder of Neko Health (transcribed as "Yelmer"/"Yalmer"). Why mentioned: Ek credits him as the real driver of Neko. Quote: "I have an amazing co-founder and partner, Yalmer, who's really the brainchild of NetGo. And he's the one who's doing most of the work, even though I'm sitting here and taking most of the credits at this point." 00:22:20

Shak Hoghouse

Ek's Prima Materia partner and the person who introduced Spotify to the host (transcribed as "Shaq"). Why mentioned: Partner in Prima Materia, and the early connection who first showed the host Spotify. Quote: "I remember the first Shaq, your partner, leaned into me at an internet summit or something and said, hey, check this out and he showed me Spotify." 00:00:49

Daniel Ek's Stardoll Recruiter (Mattias Miksche, "Matthias")

Swedish serial entrepreneur behind Stardoll, described as one of the OG entrepreneurs in the Swedish ecosystem since the dot-com bubble. Why mentioned: Recruited Ek to fix Stardoll's tech, which led to the experience Ek carried into Spotify. Quote: "there was an entrepreneur called Matthias who was kind of one of the OG entrepreneurs in the Swedish ecosystem. He had been around since the dot-com bubble." 00:47:37

Danny Rimer

Index Ventures partner (transcribed as "Danny Reimer"). Why mentioned: Persuaded Ek to help with Stardoll, in the hope that Index would fund Spotify (it did not). Quote: "Danny Reimer is very good at convincing people to do things." 00:48:30

David Friedberg

All-In co-host, founder-operator turned investor. Why mentioned: Contributed the compute-as-guardrail framing and an investor philosophy: back great founders and stay out of the way, or operate yourself. Quote: "You find amazing entrepreneur, founder, CEOs. Give them money and never look at it again and you'll be fine." 00:09:26

5. Operating Insights

Make the Downside Go Away to Close a Hard Partner

To sign skeptical record labels, Ek and his co-founder guaranteed the labels' bonuses and budgets out of their own money for a year, removing the counterparty's personal downside. The tactic reframes a scary innovation as a free option for the decision-maker.

Ek: "we basically took all of our own money that we had made from prior startups. And we said to the record labels, what if we would guarantee you that basically you'd keep your bonus for the next year and you'll make your budget for next year?" 00:04:50

Launch in the Market Where the Old Model Has Already Failed

Ek's luck was that Sweden had extreme piracy from early broadband and no legal alternative, so the industry was desperate. Choose a beachhead where the incumbent has already lost, so the buyer's alternative is zero.

Ek: "one of the worst music markets in the world was my home country, Sweden... we had super fast broadband already from the early 2000s... iTunes actually wasn't even available in the marketplace... the music industry had lost like 80% or something of its revenues." 00:03:58

Fix the Core Performance Metric Before Anything Else

At Stardoll, the highest-leverage move was cutting page load from four minutes to under a second, which unlocked traffic and funding. Find the single bottleneck that gates growth and rebuild the team around it.

Ek: "we basically re-architected the website. I hired an entirely new technical team and brought it down to under a second of load time. And obviously the traffic exploded, Sequoia invested." 00:49:25

Ship Iteratively Where Competitors Ship Once

Ek contrasts the diagnostics norm (spend years on R&D, then sell one product for a decade) with Neko's cadence of generational upgrades every few years, treating the physical product like software.

Ek: "with Neko, within this three year, when we launched and now launching in the US, we're on gen two. So we've already upgraded our diagnostic infrastructure." 00:35:13

Design Around Time Scarcity

Neko positions its product around the customer's scarcest resource, with a fast path for those who don't need consult time.

Ek: "we want to be brutally efficient with people's time. So you can actually, if you don't have any questions... you can probably get by in 30, 40 minutes." 00:24:05

6. Overlooked Insights

Neko's Data Asset May Be Worth More Than the Clinics

Ek says in passing that healthcare's data sets "are not that large," and that Neko's bet is to 10x or 100x what exists. A company that scans 100,000 people longitudinally across modalities, indexes every mole, and runs multiple trials is quietly building a proprietary, cross-country dataset in a field where such data is scarce. The clinics are the collection mechanism; the durable moat is the dataset and the predictive models trained on it, which is the same dynamic that made Spotify's recommendation engine defensible.

Ek: "for people in tech, the amount of data that exists in the healthcare system is actually not as the data sets are not that large. That's the crazy part... if we can 10x or 100x the amount of data that becomes available, we're going to be able to draw super interesting conclusions about that, not just NECO, but the whole healthcare system." 00:32:41

Multi-Country Operation Is a Hidden Scientific Advantage

Ek notes almost as an aside that healthcare systems are normally country-specific, and that Neko is one of the few operating across multiple countries from the start. That lets it compare populations (Sweden vs. UK vs. US) using identical instrumentation and protocols, which is nearly impossible in fragmented national health data and could yield uniquely comparable epidemiology.

Ek: "normally in healthcare systems, they're very country specific, right? And so this is one of the few healthcare companies that are, it's not global, but at least multi-country systems straight away. So that's also super interesting. Like, what are we finding in the UK that may or may be similar or dissimilar to the US?" 00:30:59